<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">In a study of 93 patients with severe H1N1 2009 infection requiring intensive care, 20 (21.5%) of whom received convalescent plasma therapy, the use of plasma was associated with a reduction in the viral load on days 3, 5, and 7 (
 <italic>p</italic> &lt; 0.05), cytokine and chemokine levels (
 <italic>p</italic> &lt; 0.05), and mortality (20% vs. 54.8%; 
 <italic>p</italic> = 0.011) [
 <xref ref-type="bibr" rid="CR71">71</xref>]. A systematic review by Mair-Jenkins et al. reported a statistically significant 75% reduction in the odds of mortality in SARS and severe influenza patients who received convalescent plasma [
 <xref ref-type="bibr" rid="CR72">72</xref>]. SARS patients who received convalescent plasma within 14 days after the onset of symptoms manifested better outcomes than those who received treatment later in the disease course [
 <xref ref-type="bibr" rid="CR63">63</xref>, 
 <xref ref-type="bibr" rid="CR64">64</xref>, 
 <xref ref-type="bibr" rid="CR69">69</xref>, 
 <xref ref-type="bibr" rid="CR72">72</xref>]. Serious adverse events or complications were not reported, however, the studies were of low quality and mainly uncontrolled.
</p>
